Lexeo Therapeutics, Inc. Insider Trading Activity

Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero acquired 5,930 shares of common stock on March 13, 2026 at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero acquired 5,930 shares of common stock on March 13, 2026 at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan. After this transaction, he holds 131,390 shares in total, including 104,216 restricted stock units, in a transaction exempt under Rule 16b-3(c) and 16b-3(d).

Insider Trade Summary

Grant/Award: 5,930 shares

Grant/Award 1 txn

Insider Otero Jose Manuel

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,930	$2.644	$16K

Holdings After Transaction: Common Stock — 131,390 shares (Direct)

Footnotes (2)

1. F1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
2. F2. Includes 104,216 restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lexeo Therapeutics (LXEO) report in this Form 4 filing?

Lexeo Therapeutics reported that its Chief Operating Officer, Jose Manuel Otero, acquired 5,930 shares of common stock. The acquisition occurred through the 2023 Employee Stock Purchase Plan at a price of $2.644 per share on March 13, 2026, increasing his total holdings.

How many Lexeo Therapeutics (LXEO) shares did the COO acquire and at what price?

The COO acquired 5,930 shares of Lexeo Therapeutics common stock at $2.644 per share. These shares were obtained under the 2023 Employee Stock Purchase Plan, reflecting a compensation-related acquisition rather than an open-market trade, and were reported as exempt under Rule 16b-3.

What are Jose Manuel Otero’s total Lexeo Therapeutics (LXEO) holdings after this transaction?

After the transaction, Jose Manuel Otero holds 131,390 shares of Lexeo Therapeutics common stock. This total specifically includes 104,216 restricted stock units, indicating a large portion of his position is equity-based compensation that will typically vest over time according to plan terms.

How were the new Lexeo Therapeutics (LXEO) shares acquired by the COO structured?

The new shares were acquired through Lexeo Therapeutics’ 2023 Employee Stock Purchase Plan. This plan-based acquisition is categorized as a grant or award transaction, rather than a discretionary market purchase, and is exempt from certain insider trading rules under Rule 16b-3(c) and 16b-3(d).

Does this Lexeo Therapeutics (LXEO) insider transaction involve restricted stock units (RSUs)?

The reported acquisition itself involves common stock, but the filing notes that Otero’s total 131,390-share holding includes 104,216 restricted stock units. This highlights that most of his reported equity exposure is in RSUs, which generally vest over time under company compensation programs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 09:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A	V	5,930(1)	A	$2.644	131,390(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

2. Includes 104,216 restricted stock units.

	/s/ Youjin Choi, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.